Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 15/20 | 0.67 |
| ▸ | MMP2 | P08253 | 11/20 | 0.67 |
| ▸ | MMP8 | P22894 | 1/20 | 0.67 |
| ▸ | MMP12 | P39900 | 1/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.64 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336101 | 1.00 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL6336103 | 1.00 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL2173514 | 0.87 | ADAM10 (0.67) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL3456976 | 0.86 | ADAM10 (0.60) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL27651622 | 0.86 | ADAM10 (0.60) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL2174742 | 0.84 | ADAM10 (0.64) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL3463296 | 0.84 | ADAM10 (0.64) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL20323015 | 0.84 | ADAM10 (0.89) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL14545708 | 0.84 | ADAM10 (0.89) | ADAM10MMP2MMP8MMP12ADAM17 | |
| SCHEMBL22803404 | 0.84 | ADAM10 (0.89) | ADAM10MMP2MMP8MMP12ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | claimed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | claimed |
| US-6858626-B2 | Enzyme inhibitor; antiinflammatory agents; osteoporosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | disclosed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
| EP-1087937-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065867-A1 | CYCLIC HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | MMP9, MMP2, MMP25 | ADAM10 28/4885MMP2 2/4885MMP8 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.